Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort.
Trédan O, Toulmonde M, Le Tourneau C, Montane L, Italiano A, Ray-Coquard I, De La Fouchardière C, Bertucci F, Gonçalves A, Gomez-Roca C, You B, Attignon V, Boyault S, Cassier PA, Dufresne A, Tabone-Eglinger S, Viari A, Sohier E, Kamal M, Garin G, Blay JY, Pérol D. Trédan O, et al. Among authors: gomez roca c. Cancers (Basel). 2023 Jun 30;15(13):3441. doi: 10.3390/cancers15133441. Cancers (Basel). 2023. PMID: 37444551 Free PMC article.
Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors.
Paz-Ares LG, Gomez-Roca C, Delord JP, Cervantes A, Markman B, Corral J, Soria JC, Bergé Y, Roda D, Russell-Yarde F, Hollingsworth S, Baselga J, Umana P, Manenti L, Tabernero J. Paz-Ares LG, et al. J Clin Oncol. 2011 Oct 1;29(28):3783-90. doi: 10.1200/JCO.2011.34.8888. Epub 2011 Sep 6. J Clin Oncol. 2011. PMID: 21900113 Clinical Trial.
Pitfalls and limitations of a single-centre, retrospectively derived prognostic score for phase I oncology trial participants - reply to Fussenich et al.: a new, simple and objective prognostic score for phase I cancer patients.
Olmos D, Ang JE, Gomez-Roca C, Morales-Barrera R, Vulink AJ, Massard C, Kaye S; EDDN. Olmos D, et al. Eur J Cancer. 2012 Mar;48(4):594-6. doi: 10.1016/j.ejca.2011.11.004. Epub 2011 Dec 7. Eur J Cancer. 2012. PMID: 22154652 No abstract available.
Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety.
Gomez-Roca CA, Lacroix L, Massard C, De Baere T, Deschamps F, Pramod R, Bahleda R, Deutsch E, Bourgier C, Angevin E, Lazar V, Ribrag V, Koscielny S, Chami L, Lassau N, Dromain C, Robert C, Routier E, Armand JP, Soria JC. Gomez-Roca CA, et al. Ann Oncol. 2012 May;23(5):1301-1306. doi: 10.1093/annonc/mdr383. Epub 2011 Sep 14. Ann Oncol. 2012. PMID: 21917737 Free article.
Tumour growth rates and RECIST criteria in early drug development.
Gomez-Roca C, Koscielny S, Ribrag V, Dromain C, Marzouk I, Bidault F, Bahleda R, Ferté C, Massard C, Soria JC. Gomez-Roca C, et al. Eur J Cancer. 2011 Nov;47(17):2512-6. doi: 10.1016/j.ejca.2011.06.012. Epub 2011 Jul 15. Eur J Cancer. 2011. PMID: 21763126
87 results